asco@alo33:161496 JSONTXT

Background: The use of single fraction SF radiotherapy in the treatment of PBM in the United States is no gaining clinical acceptance, especially at large institutional levels. In this cross-sectional report, e report the varying dose fractionation schemes used to treat PBM by VHA Radiation Oncology RO Centers. Methods: An electronic request as sent to 38 active VHA RO centers asking them to provide the radiation dose fractionation scheme used in the 10 most recently treated PBM - using International Classification of Diseases ICD 198.5 - secondary malignancy of bone bone marro . Data collection: 03012015 to 03162015. Dosing schemes analyzed by fraction number: single 1-2 , HPF 3-7 and MF 8-12 . We recorded variations ithin the ne 5 VHA regions: 1 to 5, and ith the 18 1 to 23 Veterans Integrated Service Netorks VISN ithin them. All are oriented East to West. Results: We collected a total of 395 events for PBM treatment interventions - 375 ere evaluable. Of the 375 cases, SF as used in 69 18 percent ; HPF 3-7 used in 75 19 percent ; MF 8 to 12 used in 190 50 percent . The most commonly used dose scheme: MF - 300cGy x10 166 44 percent of 375. HPF - 400cGy x5 - 67 17 percent of 375. SF - 800cGy x1 62 16 percent of 375. For a summary of most common dose schemes, see the Table. Conclusions: This report highlights support for ASTROs 2013 CHOOSING WISELY Campaign, and the illingness to use SF and HPF radiotherapy for PBM, ithin the VHA, though it reflected regional variations. Multiple FractionsHypofractionatedSingle Fraction300cGy x 10400cGy x 5800cGy x 1Highest Regional Usage62 percent Region 4 30 percent Region 5 30 percent Region 5 Loest Regional Usage37 percent Region 5 13 percent Region 4 14 percent Region 2 Highest VISN Usage78 percent VISN 1 45 percent VISNs 4 x0026; 12 80 percent VISN 20 Loest VISN Usage0 percent VISN 20 0 percent VISNs 5 x0026; 22 0 percent VISNs 1 x0026; 23 ,J Clin Oncol 34, 2016 suppl; abstr 10110 00:00.0,Patient and Survivor Care